Literature DB >> 8732784

Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: in vivo studies in human apoB-89, apoB-75, apoB-54.8, and apoB-31 heterozygotes.

K G Parhofer1, P H Barrett, C A Aguilar-Salinas, G Schonfeld.   

Abstract

Apolipoprotein B (apoB), the major protein component of triglyceride-rich lipoproteins secreted from the liver, plays crucial roles in the secretion, transport, and receptor-mediated clearance of lipoproteins. A minority of cases of familial hypobetalipoproteinemia is due to genetically determined truncations of apoB-100 that range in size from apoB-9 to apoB-89, but truncated apoBs smaller than apoB-27.6 were not detected in plasma. To ascertain the physiologic bases of the hypobetalipoproteinemia, we studied in vivo metabolic parameters of the products of both the normal and mutant apoB alleles in human apoB truncation/apoB-100 heterozygotes (apoB-89/apoB-100, n = 2, apoB-75/apoB-100, n = 2; apoB-54.8/apoB-100, n = 6; apoB-31/apoB-100, n = 1) using endogenous labeling with [13C]leucine, mass spectrometry, and multicompartmental modeling. All truncated forms of apoB were secreted at reduced rates. The secretion rates of apoB-89, apoB-75, apoB-54.8, and apoB-31 were 92%, 64%, 37%, and 12%, respectively, of the respective apoB-100s on a molar basis. Additionally, particles containing apoB-89, apoB-75, and apoB-54.8 had increased fractional catabolic rates (FCR), while apoB-31-containing particles had a decreased FCR. On regression analysis, the secretion rate was linearly linked to the length of the truncated apoB (r2 = 0.86, P < 0.0001), with secretion being reduced by 1.4% for each 1% of apoB truncated. The linear regression line of apoB size versus apoB secretion rate has a zero intercept for apoB secretion at apoB-28, which is consonant with the apparent absence in plasma of truncations smaller than apoB-25. We conclude that secretion of apoB in vivo is dependent on the length of the truncation of apoB, possibly because the smaller the truncated apoB, the less it is protected from intracellular degradation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732784

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  12 in total

1.  Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB.

Authors:  R A Srivastava; L Toth; N Srivastava; M E Hinsdale; N Maeda; A B Cefalu; M Averna; G Schonfeld
Journal:  Mol Cell Biochem       Date:  1999-12       Impact factor: 3.396

2.  A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia.

Authors:  Angelo B Cefalù; James P Pirruccello; Davide Noto; Stacey Gabriel; Vincenza Valenti; Namrata Gupta; Rossella Spina; Patrizia Tarugi; Sekar Kathiresan; Maurizio R Averna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-30       Impact factor: 8.311

Review 3.  Hypobetalipoproteinemia and abetalipoproteinemia.

Authors:  Francine K Welty
Journal:  Curr Opin Lipidol       Date:  2014-06       Impact factor: 4.776

4.  Measurement of apolipoprotein B in various cell lines: correlation between intracellular levels and rates of secretion.

Authors:  A Bakillah; Z Zhou; J Luchoomun; M M Hussain
Journal:  Lipids       Date:  1997-10       Impact factor: 1.880

5.  Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. Analysis of a new mouse model with a nonsense mutation in the Apob gene.

Authors:  E Kim; C M Cham; M M Véniant; P Ambroziak; S G Young
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

6.  Extreme Contrast of Postprandial Remnant-Like Particles Formed in Abetalipoproteinemia and Homozygous Familial Hypobetalipoproteinemia.

Authors:  Masa-Aki Kawashiri; Hayato Tada; Marowa Hashimoto; Matsuo Taniyama; Takamitsu Nakano; Katsuyuki Nakajima; Takeshi Inoue; Mika Mori; Chiaki Nakanishi; Tetsuo Konno; Kenshi Hayashi; Atsushi Nohara; Akihiro Inazu; Junji Koizumi; Hirotaka Ishihara; Junji Kobayashi; Tsutomu Hirano; Hiroshi Mabuchi; Masakazu Yamagishi
Journal:  JIMD Rep       Date:  2015-03-13

7.  Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.

Authors:  Maartje E Visser; Fatima Akdim; Diane L Tribble; Aart J Nederveen; T Jesse Kwoh; John J P Kastelein; Mieke D Trip; Erik S G Stroes
Journal:  J Lipid Res       Date:  2009-12-14       Impact factor: 5.922

8.  Common and rare gene variants affecting plasma LDL cholesterol.

Authors:  John R Burnett; Amanda J Hooper
Journal:  Clin Biochem Rev       Date:  2008-02

9.  Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.

Authors:  Eduardo Vilar-Gomez; Samer Gawrieh; Tiebing Liang; Adam D McIntyre; Robert A Hegele; Naga Chalasani
Journal:  J Clin Lipidol       Date:  2020-12-27       Impact factor: 4.766

10.  Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo.

Authors:  Petra Disterer; Raya Al-Shawi; Stephan Ellmerich; Simon N Waddington; James S Owen; J Paul Simons; Bernard Khoo
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.